🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EHA2025 #KOMET007 trial presented by Dr. Erba. Happy to be a part of this trial. #menin_inhibitor #youngEHA #hemasphere

A GREAT DAY 2⃣ OF #EHA25 🩸 Lets Go to #MEDTRACK for Stats Follow MEDTRACK HERE 👉MEDTRACK my.medical.watch/oncoalert/hash… MEDTRACK brought to you by OncoAlert 🚨 & Medical.watch 🧮Metrics from June 12-13, 2025 Hashtags#⃣ #EHA25 & #EHA2025 Contributors: Sanam Loghavi, MD صنم لغوی 🔬🧬

#EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts.. 1. Ven resistance mechanisms. 2. Novel targets 3. Ven triplets under development #leusm #AML #venetoclax_4_AML

Announcing the Top Post of #EHA25 Day 2 🎉🎉🎉 Coming from our friend Talha Badar on novel therapies in #AcuteMyeloidLeukemia:

Updates on treatment approaches for Essential Thrombocythemia (ET) from European Hematology Association 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #EssentialThrombocythemia #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | Naveen Pemmaraju, MD |

#EHA2025 #ALL #leusm long-term follow up of CALGB 10403 trial presented by Dr. Wendy Stock, 10 yrs OS 56%. T-cell ALL no relapses after 3 yrs. 3 pts had t-MN. Late events in B-cell ALL after 3 yrs 25%.

Great Day3️⃣of #EHA2025 Lets Go to #MEDTRACK for Stats Follow MEDTRACK HERE 👉MEDTRACK my.medical.watch/oncoalert/hash… MEDTRACK brought to you by OncoAlert 🚨 & Medical.watch 🧮Metrics from June 12-14, 2025 Hashtags#⃣ #EHA25 & #EHA2025 Contributors: Sanam Loghavi, MD صنم لغوی 🔬🧬

#EHA2025 #EHA25 #SURPASS_ET trial presented by Dr. Gill showed superior responses with RopegINF compared to anagrelide in high risk ET. #mpnsm Earlier presented at #ASCO25

#EHA2025 #EHA25 #PPM1D #TP53 Do visit our poster, highlighting the prevalence and clinical correlates of PPM1Dm in therapy-related #clonal_hematopoiesis #clonal_cytopenia Key takeaways: 1. In one of the largest cohorts, PPM1Dm +/- TP53m were significantly enriched in therapy

#EHA2025 #EHA25 #CML #youngEHA emergence of ASXL1 and tyrosine kinase domain mutation with different TKI; imatinib, 2nd generation TKI and asciminib. Best choice of TKI with respect to mutation.

#EHA2025 #EHA25 #ALL #leusm <3.3 mg/m2 vs >3.3 mg/m2 of Inotuzumab ozogamicin; impact on survival presented by Dr. Jabbour 1. Tolerance was better at lower dose with less myelosuppression. 2. Incidence of SOS was comparable. 3. Survival was better at lower dose, caveat more

#EHA2025 #EHA25 #ALL s/c blinatumomab for RR ALL, P1/1b data presented by Dr. Jabbour. 1. Given at 2 dose level, 250ug/500ug was better tolerated and selected for RP2D. 2. Responses were better compared to IV Blina. 3. Responses were seen among pts with prior IV blina exposed.

A look at FLT3 inhibitors: Quizartinib vs BMF-500 – their mechanisms, companies, and trials at European Hematology Association 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | Amer Zeidan MBBS,MHS ‏عامر زيدان |

This is really disappointing! #mdssm #high_risk_MDS

Top Oncologists from European Hematology Association 2025. Explore the latest updates from #EHA2025: t.ly/6uoHY #LARVOL #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | Fadi Haddad, MD | Eddie Cliff | calliecoombs | Talha Badar | Guilherme Perini, MD |

25 Posts Not to Miss from EHA 2025 (European Hematology Association) ASH | Nico Gagelmann | Lymphoma Coalition | Daniel Auclair | Talha Badar | Ajay Major, MD, MBA | C. Ola Landgren, M.D. | Vincent Rajkumar | Vivek Subbiah, MD | Anna Sureda | Amer Zeidan MBBS,MHS ‏عامر زيدان | Sanam Loghavi, MD صنم لغوی 🔬🧬 | Sabrina Ranero Ferrari

🚨 NEWS 🚨 U.S. FDA grants fast track designation to nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, for the treatment of patients with intermediate or high-risk #myelofibrosis Read more: loom.ly/rhBmSLo #MPN #MPNsm #MedNews

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… 1.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML | Journal of Clinical Oncology ascopubs.org/doi/full/10.12… Congratulations to Dr. Zeidner and BeatAML team. 1. Revumenib was given continuously, dose adjusted for CYP3A4i 2. Ven for 28